1 minute read
HAIRy Matters
from HAIR CUTS #3
by HairDAO
**Once received, all HAIRy rewards will be vested monthly over a two-year period**
● Ralf: 730.16, per our contract.
Advertisement
● Jumpman: 730.16. The only language model that supersedes HairGPT is JumpGPT. Jumpman’s work this month highlights PAI-1, Twist-1, Beta-2, Shh, E T, αSMA, COL17A1, ALK5, and AR–among theories on anagen, DHT, prolactin, senescence, and the arrector pilli. The VisionHair y continues to garner data that no one else in the hair loss industry has.
● Benjels: 421.55. Benjels continues to execute both mission-critical operations and gigabrain research. His operations include co-developing Discord data scraping and securitization (more on the hack in Hair Cuts #4–the world will never lose Jumpman’s research again), HairGPT, Grow, and treasury signing execution. His research includes model validity, senescence, PAI-1, epigenetics, and 3aHSD
● Herber t: 399.08. Herber t continues to lead our delivery vehicle study, while senescence, model validity, prolactin, dermal sheath, DHT, WNT, AR, NOX, and siRNA research. Visangle was especially grateful for his contributions, conferring to him the most prestigious invite a hair loss researcher can receive.
● Schmakofant: 321.61. Schmakofant carried the development of HairGPT, the first hair-focused research bot, and continues to monitor the Patient Por tal, which we could use at any day to aggregate our CosmeRNA or RU58841 data. He has more updates for HairGPT on the way–including scaling the product into a Hair Wiki that Endana wants to use to create more researchers.
● Synthetic Pug: 252.48. Synthetic Pug led research in the mesenchyme command center, hair stage cycling, cellular senescence, TGFb, ROS, AR, VEGF, NOX, and elastin.
● Endana: 179.72. Endana continues to execute on-the-ground research and operational work at a high-level. He leads our Ver teporfin research, ideates content to uplevel more researchers, and executes ad-hoc business development.
● FollicleThought: 159.92. FollicleThought continues to execute high-level business development, this month putting us in touch with Cage Bio and Zylo Therapeutics for our delivery vehicle study. He’s reached out to some bigger names too, although there’s nothing he can say yet.
